Patient education: Breast cancer guide to diagnosis and treatment (Beyond the Basics)
- Christine Laronga, MD, FACS
Christine Laronga, MD, FACS
- Moffitt Cancer Center, University of South Florida
- Section Editors
- Daniel F Hayes, MD
Daniel F Hayes, MD
- Section Editor — Breast Cancer
- Professor of Medicine
- University of Michigan School of Medicine
- Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
- Section Editor — Breast Surgery
- Associate Professor, Department of Surgery
- Yale University School of Medicine
Breast cancer is the most common female cancer in the United States, the second most common cause of cancer death in women (after lung cancer), and the leading cause of death in women ages 45 to 55. When found and treated early, breast cancer is most often curable.
Breast cancer deaths have decreased by one-third or more over the past three decades. This is due in part to increased screening, as well as earlier and improved treatment for breast cancer. Screening usually detects the disease at an earlier stage, when the chances of successful treatment are higher. Early detection and treatment of breast cancer improve survival because the breast tumor can be removed before it has a chance to spread (metastasize). In addition, there are treatments that can be used to prevent cancer cells that have escaped the breast from growing in other organs (see 'Adjuvant therapy' below). Screening recommendations are discussed in more detail elsewhere. (See "Patient education: Breast cancer screening (Beyond the Basics)".)
UpToDate contains a number of patient information articles that discuss breast cancer. The purpose of this overview is to provide a guide to the issues and questions that arise in women with newly diagnosed breast cancer. This topic can serve as a "road map" to the patient information articles that are relevant to your particular situation.
This guide will focus only on the diagnosis and treatment of breast cancer. Other articles within UpToDate discuss the risk factors for breast cancer and methods to prevent breast cancer in women who are at high risk. (See "Patient education: Factors that modify breast cancer risk in women (Beyond the Basics)" and "Patient education: Medications for the prevention of breast cancer (Beyond the Basics)".)
More detailed information about breast cancer, written for healthcare providers, is available by subscription. (See 'Professional level information' below.)
DIAGNOSING BREAST CANCER
Abnormal lump — Breast cancer can be discovered when a lump or other change in the breast or armpit is found by a woman herself or by her healthcare provider. In addition to a lump, other abnormal changes may include dimpling of the skin, a change in the size or shape of one breast, retraction (pulling in) of the nipple when it previously pointed outward, or a discoloration of the skin of the breast not related to infection or skin conditions such as psoriasis or eczema.
To evaluate a breast lump, a mammogram and a breast ultrasound are usually recommended. A breast biopsy may also be recommended (see 'Breast biopsy' below). A suspicious lump should never be ignored, even if a mammogram is negative. Up to 5 to 15 percent [1-3] of new breast cancers are not visible on a mammogram.
Mammogram — A mammogram is a very low-dose X-ray of the breast. The breast tissue is compressed for the X-ray, which decreases the thickness of the tissue and holds the breast in position, so the radiologist can find abnormalities more accurately. Each breast is compressed between two panels and X-rayed from two directions (top-down and side-to-side) to make sure all the tissue is examined. Mammograms are currently the best screening modality to detect breast cancer. Some mammograms capture images digitally, offering better clarity, the ability to adjust the image, and a decreased likelihood that the woman will need to return on a different day for repeat pictures.
3D tomosynthesis is a type of improved digital mammogram that captures multiple pictures of the breast while the breast is compressed in the two directions (top-down and side-to-side) instead of just one picture. This new technology allows the radiologist to examine multiple pictures of each breast. This is extremely helpful for seeing abnormalities that may be concealed by overlapping tissue. Additionally, finer detail is seen, which assists the radiologist in determining which lesions are benign (not cancer) and which lesions need further investigation with additional pictures [4-6].
Breast cancer is often diagnosed with a routine mammogram, before a lump or other change in the breast develops. Even if the mammogram is performed because a lump was felt in one breast, both breasts need to be examined because there is a small risk of having cancer in both breasts.
Breast ultrasound — An ultrasound uses sound waves to look at breast tissue and can tell if a lump is a fluid-filled cyst or a solid lump. An ultrasound is only used to examine a limited area of the breast, and is not yet used as a screening test of the entire breast.
Breast MRI — Magnetic resonance imaging (MRI) uses a strong magnet to create a detailed image of a part of the body. It does not use X-rays or radiation, but does require injection of a contrast agent (a material that shows up on imaging) into a vein. Prior to giving you the contrast, a blood test is performed to make sure you can have the contrast.
Breast MRI is not usually used to screen for breast cancer in most women, but can aid in the diagnosis of breast cancer in the following situations:
●Breast cancer screening for young women, particularly those with dense breasts, who have an increased risk of breast cancer (eg, mutations in the genes BRCA1 or BRCA2). (See "Patient education: Genetic testing for breast and ovarian cancer (Beyond the Basics)".)
●Evaluation for breast cancer in a woman who is diagnosed with cancer of the lymph nodes (glands) under the arm but who has no sign of breast cancer on physical examination or mammogram of the breast on that side. Sometimes the breast MRI can be used to determine if the cancer first developed in the breast, and its location.
●Evaluation of a woman with newly diagnosed breast cancer with extremely dense breasts on mammograms, because the density of the breast tissue makes the mammograms difficult to interpret.
Breast biopsy — If breast cancer is suspected, the next step is to sample the abnormal area with a biopsy to confirm the diagnosis. The best way to do this is with a needle biopsy. A fine needle aspiration may be sufficient to establish a diagnosis of breast cancer, though a core needle biopsy, which utilizes a larger gauge needle, is often preferable as it provides a larger sample to better characterize certain features of the cancer (see 'Hormone receptors' below and 'HER2' below).
If the physician feels a lump, the biopsy can be performed in the office. If the physician does not feel a lump, the biopsy can be performed with the help of an imaging study (such as mammography, ultrasound, or MRI) to determine the location of the lesion. Core needle biopsies are performed with local anesthesia and do not require sedation. The area biopsied is usually marked with a clip or another method to facilitate surgical removal if the biopsy shows cancer.
Types of breast cancer — Although there are several different types of breast cancer, they are treated similarly, with some exceptions (figure 1).
In situ breast cancer — The earliest breast cancers are called "in situ" cancers.
Ductal carcinoma in situ (DCIS) — If cancers arise in the ducts of the breast (the tubes that carry milk to the nipple when a woman is breastfeeding) and do not grow outside of the ducts, the tumor is called ductal carcinoma in situ (DCIS). DCIS cancers do not spread beyond the breast tissue. However, DCIS may develop over time into invasive cancers if not treated.
The best treatment for DCIS will depend on the size of the area of disease relative to the size of the woman's breast, the grade of the disease, and the overall health of the woman. Most women are able to be treated with removal of the cancerous area (lumpectomy) followed by radiation therapy. Surgical removal of the cancerous area alone may be an option, particularly for older women with a very small area of low grade disease that is completely removed. Women with small areas of DCIS who are being treated with lumpectomy do not need their lymph nodes checked for spread of tumor.
Women with extensive DCIS may need a mastectomy, which may be done with or without reconstruction. A sentinel lymph node biopsy, a special technique to identify and remove only the most important lymph nodes in the armpit, is usually performed at the time of mastectomy for DCIS. Large areas of DCIS have an increased chance of being associated with hidden invasive cancer. If the lymph nodes are involved by this hidden invasive cancer, this will affect treatment decisions. It is not possible to perform sentinel node biopsy after a mastectomy. (See "Patient education: Surgical procedures for breast cancer — Mastectomy and breast conserving therapy (Beyond the Basics)".)
Chemotherapy is not necessary for women with DCIS. Endocrine treatment (also called hormonal therapy) may be recommended for prevention of recurrence, particularly if the DCIS tests positive for responsiveness to estrogen (called "estrogen receptor positive" cancer) and the woman did not have a mastectomy. The drug most often used for endocrine treatment is tamoxifen. Another drug, anastrozole, may also be effective in postmenopausal women treated for DCIS, particularly those who are less than 60 years old. Endocrine treatment reduces the chances that the cancer will come back in the treated breast; it also decreases the chances of developing a new breast cancer in the other breast.
Lobular carcinoma in situ (LCIS) — If abnormal cells arise in the lobules of the breast (where breast milk is made), and they do not extend outside of the breast lobules, this is referred to as lobular carcinoma in situ (LCIS). LCIS is not considered a true cancer but instead is considered a risk factor for developing cancer in the future in either breast. Women with LCIS should see a high risk specialist and discuss risk reduction strategies, such as tamoxifen, raloxifene (a similar drug), or anastrozole, to reduce the risk of breast cancer in both breasts. In some cases, preventive mastectomies are considered for women with a strong family history of breast cancer who are diagnosed with LCIS. Women with LCIS should have regular breast cancer screening and report any changes in their breasts to their physicians. (See "Patient education: Factors that modify breast cancer risk in women (Beyond the Basics)" and "Patient education: Medications for the prevention of breast cancer (Beyond the Basics)".)
Invasive breast cancer — The majority of breast cancers are referred to as invasive breast cancers because they have grown or "invaded" beyond the ducts or lobules of the breast into the surrounding breast tissue (figure 1). Several varieties of invasive breast cancers are possible. In general, they are all treated similarly.
Features of a breast cancer that influence the choice of treatment — At the time breast cancer is diagnosed and/or treated, the cancer should be studied for the presence of two types of proteins: hormone receptors (estrogen and progesterone receptors) and HER2 (for invasive cancers). These proteins are important for selecting medical treatment. These tests are performed by the pathologist, the doctor responsible for examining the breast cancer tissue under the microscope and making the diagnosis. The pathologist will also grade the cancer.
Grade — A tumor's grade describes how aggressively it grows, although this cannot be translated into a timeframe such as a month, a year, etc. Tumors are graded on a scale of 1 to 3, where 1 is the slowest and 3 is the fastest growing type of tumor. Tumors with higher grades are more likely to need chemotherapy.
Hormone receptors — More than one-half of breast cancers require the female hormone estrogen to grow, while other breast cancers are able to grow without estrogen. Estrogen-dependent breast cancer cells produce proteins called hormone receptors, which can be estrogen receptors (ER), progesterone receptors (PR), or both.
If hormone receptors are present within a woman's breast cancer, she is likely to benefit from treatments that lower estrogen levels or block the actions of estrogen. These treatments are referred to as endocrine or hormone therapies and such tumors are referred to as hormone-responsive or hormone receptor positive.
In contrast, women whose tumors do not contain any ER or PR do not benefit from endocrine therapy, and it is not recommended. (See "Patient education: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)".)
HER2 — HER2 is a protein that is present in about one out of every five invasive breast cancers. The presence of HER2 in the breast cancer identifies women who might benefit from treatments directed against the HER2 protein. Drugs that target the HER2 protein include trastuzumab (brand name: Herceptin), pertuzumab (brand name: Perjeta), ado-trastuzumab emtansine (brand name: Kadcyla), and lapatinib (brand name: Tykerb). (See "Patient education: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)".)
HAS THE BREAST CANCER SPREAD?
Once a diagnosis of breast cancer is established, the next important questions are the following:
●How extensive is the cancer involvement within the breast?
●Is there evidence that the tumor has moved to areas outside of the breast (metastasized)?
The extent of cancer involvement within the breast is usually determined by the findings on the biopsy, the results of the mammogram and, in some cases, the results of the breast magnetic resonance imaging (MRI) scan.
Although by definition, breast cancer starts within the breast, tiny cells or pieces of the cancer may break off from the breast tumor at any point and travel to other places through the bloodstream or the lymph channels. This process is called metastasis (figure 1).
When these stray tumor cells lodge themselves in a lymph node (gland) or an organ such as the liver or the bones, they grow, eventually producing a mass or lump that can sometimes be felt (eg, if it involves the skin or the lymph nodes in the armpit). In other cases, metastases may only be evident because they cause symptoms such as bone pain and can be seen on an imaging test such as a computed tomography (CT) scan, a bone scan, or a positron emission tomography (PET) scan. The use of these studies is discussed below. (See 'Staging and the staging workup' below.)
The importance of the axillary lymph nodes — One of the first sites of breast cancer spread is to the lymph nodes located in the armpit (axilla). These nodes (referred to as axillary lymph nodes) can become enlarged and can sometimes be felt during a breast examination. However, even if the lymph nodes are enlarged, the only way to determine if they truly contain cancer is to examine a sample of the tissue under the microscope.
The presence or absence of lymph node involvement is one of the most important factors in determining the long-term outcome of the cancer (prognosis), and it often guides decisions about treatment.
●If the axillary lymph nodes contain cancer (positive nodes), there is a higher chance that cancer cells have spread elsewhere, and most of these women are advised to have adjuvant systemic therapy.
●Systemic therapy, especially chemotherapy, is recommended less often for women who have no cancer cells detected in the axillary lymph nodes (node-negative breast cancer), particularly if the tumor is small or other prognostic factors (such as estrogen receptor positivity) are all favorable. Adjuvant endocrine therapy is usually recommended to all patients with estrogen receptor positive breast cancer, even if the lymph nodes are negative, because it generally has less toxicity than chemotherapy and lowers the chances of developing a second breast cancer in the future.
Even if the axillary lymph nodes are negative, there is a small chance that the tumor has spread elsewhere in the body, and adjuvant therapy is recommended for some of these women.
Examination of the axillary lymph nodes — The axillary lymph nodes should be examined for tumor spread. This is done first by physical exam and sometimes with ultrasound. In patients with obvious cancer involvement of the axillary lymph nodes, a surgical procedure called axillary lymph node dissection is performed at the time of the breast surgery to remove all the nodes from the axilla.
In patients with early stage breast cancer who do not have obvious involvement of the axillary lymph nodes, a surgical procedure called a sentinel lymph node biopsy is often performed. In this procedure, a tracer is used to mark the lymph nodes that the cancer would go to first (also called "sentinel" nodes). These lymph nodes, which are usually under the armpit, are then removed for pathological analysis. The major benefit of the sentinel lymph node procedure is that it provides important staging information, while causing fewer problems such as arm swelling (also called lymphedema) than a more extensive axillary lymph node dissection. (See "Patient education: Lymphedema after cancer surgery (Beyond the Basics)".)
Most patients do not have cancer in their sentinel lymph nodes and will not need additional surgery. Some studies have shown that there are select patients for whom an axillary lymph node dissection is not necessary even if the sentinel lymph node(s) are positive. Patients who have three or more positive sentinel nodes, however, will require dissection of the remaining axillary lymph nodes, in case there are additional cancer-containing nodes (See "Patient education: Surgical procedures for breast cancer — Mastectomy and breast conserving therapy (Beyond the Basics)", section on 'Management of axillary lymph nodes'.)
21 gene test (Oncotype DX) — A genetic test called Oncotype DX can be performed on the tumor tissue to help with decision-making about chemotherapy, in particular for women with ER positive, HER2 negative, and node-negative breast cancer. The test looks at 21 different genes in order to evaluate the genetic make-up of the tumor, and provides a number score to help predict the chance of recurrence. The score is called the "recurrence score" and the results range from 0 to 100. Cancer doctors will often use this information, in combination with other information about the patient and tumor, to guide decision-making about the need for chemotherapy. In general, patients with a low recurrence score whose cancers also have other low-risk features may not need chemotherapy, whereas those with a high score benefit more from chemotherapy. Antiestrogen therapy is typically administered to patients with hormone receptor positive disease, regardless of the recurrence score. (See 'Adjuvant therapy' below.)
Staging and the staging workup — Doctors who care for cancer patients (oncologists) use a standard set of abbreviations, called the TNM staging system, to describe the stage of individual cancers. The "T" stands for the primary tumor, the "N" stands for the status of the regional lymph nodes, and the "M" stands for the presence or absence of metastases to other organs. The T, N, and M designations are then grouped together to form the stage grouping of a breast cancer, which ranges from stage I (least advanced) to IV (most advanced). Stage 0 cancer is the categorization for patients with DCIS alone. The "stage" of the cancer is an indication of whether and how far it has spread. Stage and grade are often confused by patients, but they are not the same thing (see 'Grade' above).
Tumor size (T) and nodes (N) — To establish the stage of a breast cancer, the first step is to evaluate the size of the tumor (T) and establish whether the lymph nodes have cancer in them or not (N). This is accomplished with:
●A complete physical, including careful examination of the breast and lymph nodes
●Mammogram (and, if indicated, other means of breast imaging such as ultrasound or breast MRI)
●Pathologic examination of the cancer and lymph nodes after they are removed
Metastases (M) — If any cancer is detectable outside of the breast, these deposits are called metastases (M).
Several "staging" imaging studies may be done to help determine if the cancer has spread beyond the breast and axillary lymph nodes. These may include:
●CT scan of the chest
●CT scan of the abdomen and pelvis
Not all of these studies will be recommended during the staging process. Indeed, for most women (including those who have no suspicious symptoms and who have small tumors with negative or only a few positive lymph nodes) nothing is needed for staging beyond the physical exam. The components of the staging evaluation are covered in more detail elsewhere. (See "Patient education: Surgical procedures for breast cancer — Mastectomy and breast conserving therapy (Beyond the Basics)".)
Stage I and II breast cancer — Women with stage I or II breast cancers are said to have early stage localized breast cancer. A stage I breast cancer refers to a tumor less than 2 cm (0.8 inches) in size that is node-negative.
Stage II tumors are those with spread to the axillary lymph nodes and/or a tumor size larger than 2 cm but smaller than 5 cm (about 2 inches).
Stage III breast cancers — Women with stage III tumors are referred to as having locally advanced breast cancer. These consist of large breast tumors (greater than 5 cm, or about 2 inches, across), those with extensive axillary nodal involvement (more than 10 lymph nodes with cancer), nodal involvement of both axillary and internal mammary nodes (behind the ribs of the breast with cancer) at diagnosis, or nodal involvement of the soft tissues above or below the collarbone (termed the supraclavicular and infraclavicular lymph nodes, respectively) (table 1).
A tumor is also designated as stage III if it extends to underlying muscles of the chest wall or the overlying skin. Inflammatory breast cancer, a rapidly growing form of cancer that makes the breast appear red and swollen, is at least stage III, even if it is small and does not involve lymph nodes.
Stage IV breast cancer — Stage IV breast cancer refers to tumors that have metastasized to areas outside the breast and lymph nodes to the bones, lungs, liver, or other organs. The primary tumor may be any size, and there may be any number of affected lymph nodes. This is referred to as metastatic breast cancer (table 1).
OVERVIEW OF TREATMENT
The treatment of breast cancer must be individualized and is based upon several factors. Optimal management in most cases requires collaboration between surgeons (breast cancer surgeons and reconstructive surgeons, who are typically plastic surgeons) and physicians who specialize in radiation and medical oncology. Each woman should discuss the available treatment options with her doctors to determine what treatment is best for her.
Early stage localized breast cancer — Women with stage I and II breast cancers are treated similarly, with minor exceptions. Two surgical options are available for treating localized breast cancer: mastectomy (removal of the breast) and breast conserving surgery (removal of the cancerous tissue, called lumpectomy).
Breast conserving therapy (BCT) consists of breast conserving surgery, which may also be referred to as wide excision, quadrantectomy, or partial mastectomy. Breast conserving therapy also requires radiation therapy to reduce the chances of cancer coming back in the same breast. However, there are some patients for whom radiation therapy to the remaining breast may not be necessary, particularly elderly patients who have small, node-negative cancers that are hormone receptor positive. The combination of surgery and radiation usually results in cosmetically acceptable preservation of the breast without compromising breast cancer outcomes.
In centers that specialize in breast cancer treatment, approximately 60 percent of women with early stage breast cancer are candidates for BCT. In 25 to 50 percent of women, there are medical, cosmetic, and/or social and emotional reasons for having a mastectomy rather than BCT. However, assuming that the patient is considered a good candidate for BCT, survival outcomes are the same whether BCT or mastectomy is performed. (See "Patient education: Surgical procedures for breast cancer — Mastectomy and breast conserving therapy (Beyond the Basics)".)
Radiation therapy to the chest wall and surrounding lymph node areas may also be recommended for patients who have had a mastectomy. Factors such as positive lymph nodes, large tumors, and positive margins play into the decision.
Breast reconstruction is an important option for women who undergo mastectomy and may be considered at the time of the mastectomy or at a later date. Consultation with a plastic surgeon prior to the mastectomy is essential if immediate reconstruction is desired. Knowledge of the need for postmastectomy radiation may influence the plastic surgeon's decision as to the timing of the reconstruction (immediate or delayed).
Adjuvant therapy — Systemic (body-wide) anti-cancer treatment that is given before or after surgery is called "adjuvant systemic therapy." The goal of adjuvant systemic therapy is to eliminate or prevent the growth of any cancer cells that may have escaped the breast and that might grow in other organs (metastases). The first place that breast cancer spreads is the lymph nodes under the armpit (axilla). When breast cancer metastasizes to lymph nodes in the axilla (the axillary lymph nodes), the chance for cure is lower than when it is only in the breast. Patients with metastases or cancer cells in other organs such as the liver, lung, or bone are rarely cured. However, adjuvant systemic therapy may prevent metastases in a large fraction of patients and thus cure many women who would not be cured otherwise. Adjuvant systemic therapy, therefore, has become an important component of breast cancer treatment because it significantly decreases the chance that a cancer will return, especially in situations where the cancer had already spread to the axillary lymph nodes. This, in turn, improves the chances of surviving breast cancer.
Adjuvant systemic therapy is recommended for the vast majority of women with stage II breast cancer, and for some women with stage I disease. (See "Patient education: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)" and "Patient education: Early-stage breast cancer treatment in postmenopausal women (Beyond the Basics)".)
There are three types of adjuvant systemic therapy. Some women may receive multiple types of these treatments depending on their tumor characteristics:
●Endocrine therapy (also called hormone or antiestrogen treatment) – Endocrine therapy is only recommended for women with ER positive breast cancer. Because it has very few life-threatening side effects and is so effective, it is recommended for almost all women with ER positive disease, regardless of stage. Endocrine therapy reduces the odds of a breast cancer recurrence by nearly 50 percent. There are two types of endocrine therapies that are used in the adjuvant setting: selective estrogen receptor modulators (SERMs) such as tamoxifen or raloxifene, and aromatase inhibitors (AIs).
●Anti-HER2 therapy – Anti-HER2 therapy is usually recommended for patients whose tumors make a lot of HER2 (see 'HER2' above). Trastuzumab (brand name: Herceptin) is approved for adjuvant treatment in the United States, and pertuzumab (brand name: Perjeta) is approved for "neoadjuvant" (before surgery) treatment. The main risk of trastuzumab is a small risk of heart damage. Doctors usually monitor patients with echocardiograms (imaging tests of the heart).
●Chemotherapy – There is no particular marker to determine whether or not chemotherapy should be given. Instead, treatment decisions are based on many factors, such as the stage and grade of a tumor, and whether it lacks hormone receptors or makes a lot of the HER2 protein. The results of the 21 gene test (Oncotype DX) may help identify patients with ER positive, HER2 negative, node-negative breast cancer whose prognosis is so good that chemotherapy is unlikely to provide benefit (see '21 gene test (Oncotype DX)' above). There are many types of chemotherapies used in the adjuvant setting, and they are usually given in combination or in a sequential manner. Your oncologist will decide the regimen that is best for you.
Locally advanced and inflammatory breast cancer — Although not precisely defined, the term "locally advanced" implies one or more of the following: a tumor larger than 5 cm (about 2 inches), many palpable positive surrounding lymph nodes, cancer nodules or ulceration in the skin overlying the breast, or fixation of the cancer to the chest wall behind the breast. Another form of locally advanced breast cancer is "inflammatory breast cancer," which causes swelling, redness, or thickening of the skin due to its invasion by cancer cells. The likelihood of curing locally advanced and inflammatory breast cancer is lower than for smaller cancers and cancers that do not have any of these physical findings, but is still possible with appropriate treatment. Treatment generally includes a combination of chemotherapy, surgery, and radiation therapy. Additional therapies may include endocrine therapy (if the tumor is hormone receptor-positive) or trastuzumab (if the tumor is HER2-positive). In most cases, systemic therapy (chemotherapy, trastuzumab, and sometimes endocrine therapy) is given before surgery (when this happens, it is called "neoadjuvant therapy"). In fact, the treatment for locally advanced breast cancer is very similar to that for non-locally-advanced disease, except that a larger proportion of patients are treated with mastectomy rather than BCT (although BCT may be an option in some cases in which there has been a good response to neoadjuvant therapy), and almost all patients receive radiation therapy after surgery. (See "Patient education: Locally advanced and inflammatory breast cancer (Beyond the Basics)".)
Metastatic breast cancer — Few, if any, patients with metastatic breast cancer are cured (where "cure" means that the disease goes completely away and never comes back). However, substantial progress has been made in improving the length of time patients live with metastatic breast cancer, and the quality of life they have during that time. To achieve these latter goals, doctors usually treat metastatic breast cancer with the approach that is most likely to reduce the symptoms related to the cancer with as few side effects as possible. This strategy is usually accomplished with a judicious use of "systemic therapy" that treats the whole body, such as chemotherapy, endocrine therapy, trastuzumab, or some combination of these options. Surgery and radiation therapy that are more localized are used to control disease in certain areas, such as bone metastases that are particularly symptomatic or about to cause a fracture, brain or spinal cord metastases, and skin metastases on the chest that are causing symptoms. Not all patients do well with treatment of metastatic disease, but in general for most patients, treatment can prolong life, delay the progression of the cancer, relieve cancer-related symptoms, and improve quality of life. (See "Patient education: Treatment of metastatic breast cancer (Beyond the Basics)".)
The choice of treatment for metastatic breast cancer depends upon many individual factors, including features of the woman's breast cancer (especially whether it produces hormone receptors and HER2), the expected response of the cancer to various therapies, treatment-related side effects, the extent and location of metastases, and a woman's personal preferences.
Each woman should discuss the available treatment options with her physician to determine which choice is best for her. (See "Patient education: Treatment of metastatic breast cancer (Beyond the Basics)".)
There are many unanswered questions about the evaluation and treatment of breast cancer. Many advances have been made that have led to more effective and less toxic treatments over the last several decades. Ask your doctor if you are eligible for a clinical trial and then decide if participation is right for you.
Videos addressing common questions about clinical trials are available from the American Society of Clinical Oncology (http://www.cancer.net/pre-act).
WHERE TO GET MORE INFORMATION
Your healthcare provider is the best source of information for questions and concerns related to your medical problem.
This article will be updated as needed on our web site (www.uptodate.com/patients). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.
Patient level information — UpToDate offers two types of patient education materials.
The Basics — The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.
Patient education: Breast cancer (The Basics)
Patient education: Breast cancer screening (The Basics)
Patient education: Common breast problems (The Basics)
Patient education: Genetic testing for breast and ovarian cancer (The Basics)
Patient education: Breast reconstruction after mastectomy (The Basics)
Patient education: Choosing treatment for early-stage breast cancer (The Basics)
Patient education: Ductal carcinoma in situ (DCIS) (The Basics)
Patient education: Inflammatory breast cancer (The Basics)
Patient education: Breast biopsy (The Basics)
Patient education: Sentinel lymph node biopsy for breast cancer (The Basics)
Beyond the Basics — Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.
Patient education: Factors that modify breast cancer risk in women (Beyond the Basics)
Patient education: Medications for the prevention of breast cancer (Beyond the Basics)
Patient education: Breast cancer screening (Beyond the Basics)
Patient education: Genetic testing for breast and ovarian cancer (Beyond the Basics)
Patient education: Surgical procedures for breast cancer — Mastectomy and breast conserving therapy (Beyond the Basics)
Patient education: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)
Patient education: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)
Patient education: Lymphedema after cancer surgery (Beyond the Basics)
Patient education: Early-stage breast cancer treatment in postmenopausal women (Beyond the Basics)
Patient education: Locally advanced and inflammatory breast cancer (Beyond the Basics)
Patient education: Treatment of metastatic breast cancer (Beyond the Basics)
Professional level information — Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.
Adjuvant systemic therapy for HER2-positive breast cancer
Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer
Overview of the treatment of newly diagnosed, non-metastatic breast cancer
Breast conserving therapy
Breast imaging for cancer screening: Mammography and ultrasonography
Clinical manifestations and diagnosis of a palpable breast mass
Diagnostic evaluation of women with suspected breast cancer
General principles on the treatment of early-stage and locally advanced breast cancer in older women
Genetic counseling and testing for hereditary breast and ovarian cancer
Management of patients at high risk for breast and ovarian cancer
Mastectomy: Indications, types, and concurrent axillary lymph node management
Tumor, Node, Metastasis (TNM) staging classification for breast cancer
The following organizations also provide reliable health information.
●National Cancer Institute
●American Society of Clinical Oncology
●National Comprehensive Cancer Network
●American Cancer Society
- Sprague BL, Arao RF, Miglioretti DL, et al. National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 2017; 283:59.
- Lehman CD, Arao RF, Sprague BL, et al. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 2017; 283:49.
- Renart-Vicens G, Puig-Vives M, Albanell J, et al. Evaluation of the interval cancer rate and its determinants on the Girona Health Region's early breast cancer detection program. BMC Cancer 2014; 14:558.
- Lourenco AP, Barry-Brooks M, Baird GL, et al. Changes in recall type and patient treatment following implementation of screening digital breast tomosynthesis. Radiology 2015; 274:337.
- Gao Y, Babb JS, Toth HK, et al. Digital Breast Tomosynthesis Practice Patterns Following 2011 FDA Approval: A Survey of Breast Imaging Radiologists. Acad Radiol 2017; 24:947.
- Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol 2016; 17:1105.
All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.